Universität zu Köln

Broeckelmann, Paul J., Mueller, Horst, Gillessen, Sarah, Yang, Xiaoqin, Koeppel, Larissa, Pilz, Veronika, Marinello, Patricia, Kaskel, Peter, Raut, Monika, Fuchs, Michael, Borchmann, Peter, Engert, Andreas and von Tresckow, Bastian (2022). Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia, 36 (3). S. 772 - 781. LONDON: SPRINGERNATURE. ISSN 1476-5551

Full text not available from this repository.

Abstract

To evaluate patterns of rrHL after contemporary first-line treatment we studied 409 patients with first rrHL (HD13: n = 87, HD14: n = 118, HD15: n = 188, HDR3i: n = 51) at a median age of 37.4 years (18.4-76.8) from the GHSG database. Time to first relapse was <= 12 months in 49% and stage III/IV rrHL present in 52% of patients. In total, 291 patients received high-dose chemotherapy and autologous stem-cell transplantation (ASCT) and intended ASCT failed in 38 patients. ASCT was primarily not intended in 80 patients largely due to low risk disease or age/comorbidities. Overall, 10-year progression-free (PFS) and overall survival (OS) rates after first relapse were 48.2% (95% CI 41.9-54.2%) and 59.4% (95% CI 53.0-65.2%), respectively, with significant differences between subgroups. Inferior survival was observed with no ASCT due to advanced age/comorbidities (five-year PFS 36.2%, 95% CI 17.7-55.0%) or failure of salvage therapy (five-year PFS 36.3%, 95% CI 19.7-53.2%). Similarly, presence of primary refractory disease or stage IV at rrHL conferred inferior survival. In patients with low-risk disease, however, survival appeared favorable even without ASCT (10 y PFS 72.6%, 95% CI 53.7-84.8%). We herein confirm the curative potential of current rrHL treatments providing a robust benchmark to evaluate novel therapeutic strategies in rrHL. Approximately 50% of rrHL patients experienced a consecutive relapse.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Broeckelmann, Paul J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mueller, Horst UNSPECIFIED UNSPECIFIED UNSPECIFIED Gillessen, Sarah UNSPECIFIED UNSPECIFIED UNSPECIFIED Yang, Xiaoqin UNSPECIFIED UNSPECIFIED UNSPECIFIED Koeppel, Larissa UNSPECIFIED UNSPECIFIED UNSPECIFIED Pilz, Veronika UNSPECIFIED UNSPECIFIED UNSPECIFIED Marinello, Patricia UNSPECIFIED UNSPECIFIED UNSPECIFIED Kaskel, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Raut, Monika UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuchs, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED von Tresckow, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-588394
DOI:	10.1038/s41375-021-01442-8
Journal or Publication Title:	Leukemia
Volume:	36
Number:	3
Page Range:	S. 772 - 781
Date:	2022
Publisher:	SPRINGERNATURE
Place of Publication:	LONDON
ISSN:	1476-5551
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; OPEN-LABEL; FINAL ANALYSIS; EARLY-STAGE; PHASE-II; TRIAL; CHEMOTHERAPY; INTENSITY; SURVIVAL Multiple languages Oncology; Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/58839